

SOURCES DES FIGURES ET DES TABLEAUX

Figures

- 1.1 & 1.2 GLOBOCAN 2000*
- 1.3 WHO/TDR Image Library/Crump
- 1.4 2000*
- 1.5 CDC Public Health Image Library, Atlanta, USA/Dr. Edwin P. Ewing, Jr.
- 1.6 Anna White, Coordinator, Global Partnerships for Tobacco Control, PO Box 19405, Washington, DC 20036, USA
- 1.7 & 1.8 GLOBOCAN 2000*
- 1.9 & 1.10 IARCPress
- 2.1 A. J. Sasco, IARC
- 2.2 B.W. Stewart, Australie
- 2.3 SPL/Cosmo
- 2.4 Archives photographiques numériques de l'OMS/H. Anenden
- 2.5 Reproduit d'après *Eur J Cancer*, Vol. 35, F. Levi, F. Lucchini, E. Negri, P. Boyle, C. La Vecchia C, Cancer mortality in Europe, 1990-94, and an overview of trends from 1955 to 1994, 1477-1516, copyright 1999, avec la permission de Elsevier Science
- 2.6 P. Boffetta, CIRC/American Cancer Society, E.C.Hammond (1966) *Natl Cancer Inst Monogr*, 19 : 127-204; T. Hirayama (1985) A cohort study of cancer in Japan. In Blot WJ, Hirayama T, Hoel DG eds. *Statistical Methods in Cancer Epidemiology*. Hiroshima, Fondation pour la Recherche sur les Effets des Radiations, 73-91
- 2.7 Reproduit d'après *Eur J Cancer Prev*, Vol. 8, M. Pandey, A. Mathew, M.K. Nair, Global perspective of tobacco habits and lung cancer: a lesson for third world countries, 271-279, Copyright 1999, avec la permission de Elsevier Science
- 2.8 D'après C.J.L. Murray et al., Tobacco, in C.J.L. Murray and A.D. Lopez (1996) *Quantifying Global Health Risks: the Burden of Disease Attributable to Selected Risk Factors*. Cambridge, Harvard University Press
- 2.9 A.D. Lopez N.E. Collishaw, T. Piha (1994) A descriptive model of the cigarette epidemic in developed countries. Tobacco Control, 3:242-247, avec la permission du BMJ Publishing Group
- 2.10 P. Boffetta, CIRC
- 2.11 A.M. Thompson, Royaume-Uni
- 2.12 P. Boffetta, CIRC/ Programme des Monographies du CIRC
- 2.13 D. Jernigan, Marin Institute, California, USA
- 2.14 Adapté, d'après A.J. Tuyns, J. Estève, L. Raymond, Berrino, E. Benhamou et al. (1988) Cancer of the larynx/hypopharynx, tobacco and alcohol: IARC international case-control study in Turin and Varese (Italy), Zaragoza and Navarra (Spain), Geneva (Switzerland) and Calvados (France), *Int J Cancer*, 41(4):483-491
- 2.15 D. Jernigan, Marin Institute, California, USA
- 2.16 Graphics and Audiovisual section, NCI Office of Cancer Communications, USA
- 2.17 - 2.19 IARCPress
- 2.20 Groupe Charbonnages de France; HBL Audiovisuel/Synchro
- 2.21 & 2.22 IARCPress
- 2.23 Pan Photographics, Via Le Pietre 15, Vico Equense, NA 80069, Italie
- 2.24 Archives photographiques numériques de l'OMS/OPS/Armando Waak
- 2.25 Pascale Dia, CIRC
- 2.26 Archives photographiques numériques de l'OMS/H. Anenden
- 2.27 - 2.31 R. Montesano, CIRC
- 2.32 IARCPress/T.W. Kensler, Department of Environmental Health Sciences, Johns Hopkins School of Hygiene and Public Health, Baltimore, MD 21205, USA
- 2.33 H. Ohgaki, CIRC
- 2.34 Wellcome Trust Medical Photographic Library, Royaume-Uni
- 2.35 IARCPress
- 2.36 'Chernobillinterinform' 1996, 255620 Chernobillinterinform, 1996 (25560, Chernobill, Kiev region, B. Chmelnitcky street, 1a)
- 2.37 Pan Photographics, Via Le Pietre 15, Vico Equense, NA 80069, Italie
- 2.38 NRPB (2001) *ELF Electromagnetic fields and the risk of cancer*, Vol. 12. No. 1, National Radiological Protection Board, Chilton Didcot, Oxon OX11 0PO, Royaume-Uni
- 2.39 H. N. Ananthaswamy, Department of Immunology, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, Texas 77030, USA
- 2.40 USA Environmental Protection Agency
- 2.41 Public Health Image Library CDC, USA/Dr Erskine Palmer
- 2.42 Wellcome Trust Medical Photographic Library, Royaume-Uni
- 2.43 Avec la permission d'Oxford University Press, H. zur Hausen (2000) Papillomaviruses causing cancer, *J Natl Cancer Inst*, 92(9): 695. Adapté, d'après H. zur Hausen (1991) Human Papillomaviruses in the Pathogenesis of Anogenital Cancer, *Virology*, 184, 9-13.
- 2.44 & 2.45 IARCPress
- 2.46 Public Health Image Library, CDC, USA/Dr Edwin P. Ewing, Jr.
- 2.47 & 2.48 S. Franceschi, CIRC
- 2.49 Copyright de l'American Society for Investigative Pathology. F. Chisari (2000), Viruses, Immunity and Cancer: Lessons from Hepatitis B, *Am J Pathol*, 156, 1118-1131
- 2.50 IARCPress

- 2.51 Public Health Image Library, CDC, USA/Dr Edwin P.Ewing, Jr.
- 2.52 Istituto Nazionale dei Tumori, Milan, Italie; Deutsches Krebsforschungszentrum, Heidelberg, Allemagne; National Institute of Public Health and Environmental Protection (RIVM), Bilthoven, Pays-Bas
- 2.53 T. Norat et E. Riboli, CIRC
- 2.54 D. Graham, USA/Adapté, d'après Fig. 2, S. Tsugane, M. Akabane, T. Inami, S. Matsushima, T. Ishibashi et al. (1991) Urinary salt excretion and stomach cancer mortality among four Japanese populations. *Cancer Causes Control*, 2: 165-8, avec l'aimable permission des Kluwer Academic Publishers
- 2.55 IARCPress
- 2.56 B.W. Stewart, Australie
- 2.57 Etude EPIC /Dr Riboli, CIRC
- 2.58A Carte dérivée des statistiques de consommation alimentaire de la FAO/T. Norat, E. Riboli, CIRC.
- 2.58B GLOBOCAN 2000*
- 2.59 Public Health Image Library, CDC, USA/James Gathany
- 2.60 Avec la permission du Multi-Organ Transplant Programme, Royaume-Uni
- 2.61 & 2.62 N.L. Harris, Department of Pathology, Warren 2, Massachusetts General Hospital, Fruit Street, Boston, MA 02114, USA
- 2.63 R.D. Brunning, Department of Laboratory Medicine and Pathology, University of Minnesota Hospital, 420 Delaware Street SE, Box 609, Minneapolis, MN 55455-0385, USA
- 2.64 C. A. Clarke (2001) Changing incidence of KS and NHL among young men in San Francisco, *AIDS*, 15(14): 1913-1914, copyright Lippincott Williams & Wilkins
- 2.65 E.J. Stanbridge and W. K. Cavane, Tumor Suppressor Genes, in, R. Weinberg, ed (1989) *Oncogenes and the Molecular Origins of Cancer*, Cold Spring Harbor Laboratory Press
- 2.66 & 2.6 Wellcome Trust Medical Photographic Library, Royaume-Uni.
- 2.68 C. Bonnardel, CIRC
- 2.69 IARCPress
- 2.70 Wellcome Trust Medical Photographic Library, Royaume-Uni
- 2.71 Reproduit avec la permission de Elsevier Science. Collaborative Group on Hormonal Factors in Breast Cancer (1996) Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies, *Lancet*, 347, 1713-27
- 2.72 WHO/TDR Image Library/Crump
- 3.1 C. Harris, National Cancer Institute, NIH, Bethesda, MD 20892-4255, USA
- 3.2 E.R. Fearon and B. Vogelstein (1990) A genetic model for colorectal tumorigenesis, *Cell*, 61: 759-767
- 3.3 Reproduit d'après *Eur J Cancer*, Vol. 35(3), M. Ilyas, J. Straub, IP Tomlinson, W.F. Bodmer, Genetic pathways in colorectal and other cancers, 335-35, Copyright (1999), avec la permission de Elsevier Science
- 3.4 Y. Nakanuma, Second Département de Pathologie, Faculté de Médecine de l'Université Kanazawa, Takaramachi 13-1 920-8640
- 3.5 L.H. Sobin, USA
- 3.6 N.J. Carr, Department of Cellular Pathology, Southampton General Hospital, Tremona Road, Southampton SO16 6YD, Royaume-Uni
- 3.7 A. Barbin, CIRC
- 3.8 B.W. Stewart, Australie
- 3.9 - 3.11 Reproduit avec la permission de *Nature*. J.H. Hoeijmakers (2001) Genome maintenance mechanisms for preventing cancer. *Nature* 411, 366-374, Copyright (2001) Macmillan Magazines Ltd.
- 3.12 J.R. Jass, Pathology Department, Grad. Med. School, University of Queensland, Herston Road, 4006 Brisbane, Queensland, Australie
- 3.13 Adapté, d'après C.R. Boland, F.A. Sinicrope, D.E. Brenner, J.M. Carethers (2000) Colorectal cancer prevention and treatment. *Gastroenterology*, 118(2 Suppl 1): S115-28
- 3.14 J. Hall, CIRC
- 3.15 P. Hainaut, CIRC
- 3.16 B. W. Stewart, Australie.
- 3.17 Permission de J. Couturier, Unité de Cytogénétique, Institut Curie, 26, rue d'Ulm, 75248 Paris, France
- 3.18 Adapté, d'après P.H. Rabbitts, Tumour suppressor genes, in J. Kendrew and E. Lawrence, eds (1994) *The Encyclopaedia of Molecular Biology*, Blackwell Science
- 3.19 P. Hainaut, CIRC
- 3.20 Loréal Recherche, Centre Charles Zviak, 92583 Clichy, France
- 3.21 P. Hainaut, CIRC
- 3.22 P. Hainaut, CIRC / logiciel RasMol, version 2.6; coordinate file for p53:DNA crystal data 1TUP in the Protein Brookhaven Database. Données de Y. Cho, S. Gorina, P.D. Jeffrey, N.P. Pavletich. Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations (1994) *Science*, 265(5170): 346-355
- 3.23 P. Hainaut, CIRC
- 3.24 P. Hainaut, CIRC / Base de données du CIRC des mutations de TP53, R6, 2002
- 3.25 C.A. Rubio, Pathologie gastrointestinale et hépatique, Département de Pathologie, Institut Karolinska, 171 76 Stockholm, Suède
- 3.26 S. Zeitlin and K. Sullivan, Department of Cell Biology, The Scripps Research Institute 10550 N. Torrey Pines Road, La Jolla, CA 92037, USA
- 3.27 & 3.28 P. Hainaut, CIRC
- 3.29 J.W. Shay, W.E. Wright, University of Texas Southwestern Medical Center, Department of Cell Biology Room K2-206 5323 Harry Hines Boulevard, Dallas, TX 75390-9039, USA. Les sondes centromériques et télomériques ont été fournies par S. Gryaznov, de la Geron Corporation, Menlo Park, CA, et l'image numérique a été prise par Y. Zou
- 3.30 & 3.31 H. Yamasaki, Japon

- 3.32 M. Mesnil et H. Yamasaki (2000) Bystander effect in herpes simplex virus-thymidine kinase/ganciclovir cancer gene therapy: role of gap junctional intercellular communication. *Cancer Res*, 60: 3989-3999
- 3.33 J. F.R. Kerr and B.V. Harmon (1991) Definition and incidence of apoptosis, in *Apoptosis: the Molecular Basis of Cell Death*, eds L.D. Tomei and F.O. Cope. Cold Spring Harbour Laboratory Press, 5-29
- 3.34 Reproduit avec la permission de Nature. B.B. Zhou, S.J. Elledge (2000) The DNA damage response: putting checkpoints in perspective. *Nature*, 408: 433-439, Copyright (2000) Macmillan Magazines Ltd.
- 3.35 IARC Press
- 3.36 N.J. Carr, Department of Cellular Pathology, Southampton General Hospital, Tremona Road. Southampton SO16 6YD, Royaume-Uni
- 3.37 Reproduit avec la permission de Nature, M.O. Hengartner (2000) The biochemistry of apoptosis, *Nature*, 407, 770-6. Copyright (2000) Macmillan Magazines Ltd.
- 3.38 J.C. Bourdon, Department of Surgery and Molecular Oncology, Ninewells Hospital, University of Dundee, Ecosse, Royaume-Uni
- 3.39 Adapté, d'après A.A. Adjei, USA
- 3.40 Reproduit d'après *Eur J Cancer*, Vol. 36, Beavon I, The E-cadherin complex in tumour metastasis: structure, function, regulation, 1607-1620. Copyright (2000), avec la permission de Elsevier Science
- 3.41 Reproduit d'après *Eur J Cancer*, Vol. 36, J.A. Wyke, Overview-burgeoning promise in metastasis research, 1589-1594. Copyright 2000, avec la permission de Elsevier Science
- 3.42 C. Fenoglio-Preiser, Department of Pathology, University of Cincinnati, School of Medicine, 231 Bethesda Avenue, POB 670529, Cincinnati, OH 45267-0529, USA
- 3.43 R.C. Janzer, Division de Neuropathologie, Institut universitaire de Pathologie, 27 rue du Bugnon, CH 1011 Lausanne, Suisse
- 3.44 R.D. Rubens, Clinical Oncology Unit, Guys Hospital, London SE1 9RT, Royaume-Uni
- 3.45 S. Eccles, Royaume-Uni
- 4.1 Reproduit d'après R. Doll, R. Peto, K. Wheatley, R. Gray, I. Sutherland (1994) Mortality in relation to smoking: 40 years' observations on male British doctors. *BMJ*, 309(6959): 901-911, avec la permission du *BMJ* Publishing Group
- 4.2 Adapté, d'après F. Faggiano, T. Partanen, M. Kogevinas, P. Boffetta (1997) *Socioeconomic differences in cancer incidence and mortality* (IARC Scientific Publication 138), 65-176.
- 4.3 R. Peto, S. Darby, H. Deo, P. Silcocks, E. Whitley et al. (2000) Smoking, smoking cessation, and lung cancer in the Royaume-Uni since 1950: combination of national statistics with two case-control studies. *BMJ*, 321(7257): 323-329, avec la permission du *BMJ* Publishing Group
- 4.4 T. Lancaster, L. Stead, C. Silagy, A. Sowden (2000) Effectiveness of interventions to help people stop smoking: findings from the Cochrane Library. *BMJ*, 321(7257) : 355-358, avec la permission du *BMJ* Publishing Group. Données originales de Silagy et al. (2000) *Nicotine replacement therapy for smoking cessation*, Cochrane Library, Issue 3, Oxford: Update Software
- 4.5 R. Peto, Z.M. Chen, J. Boreham (1999) Tobacco the growing epidemic. *Nat Med* 5 (1);15-17 and B.Q. Liu, R. Peto, Z.M. Chen, J. Boreham, Y.P. Wu et al. (1998) Emerging tobacco hazards in China: 1. Retrospective proportional mortality study of one million deaths. *BMJ*, 317(7170):1411-22
- 4.6 'La verité si j'fume' permission de la Fédération Nationale des Centres de Lutte Contre le Cancer et Aventis Pharma SA; 'Il suffit de dire NON', permission de l'Association Tunisienne de Lutte Contre le Cancer; "Quanto ti costa fumare?", Istituto Nazionale per la Ricerca sul Cancro, Gênes, Italie; "Merci de ne pas fumer", copyright du Comité National Contre le Tabagisme, 31, avenue Michel Bizot, 75012 Paris, France, www.cnct.org; "Animaux qui fument" & "NO smoking", permission de l'Association japonaise de Santé publique. A. J. Sasco, CIRC
- 4.7 Centers for Disease Control and Prevention (2000) *Mortality and Morbidity Weekly Report*, 49:1066-1069, <http://www.cdc.gov/mmwr>
- 4.8 Graphics and Audiovisual section, NCI Office of Cancer Communications, USA
- 4.9 P. Boffetta, CIRC/Adapté, d'après K. Magnus, A. Andersen, A.C. Hogetveit (1982) Cancer of respiratory organs among workers at a nickel refinery in Norway. *Int J Cancer*, 30(6): 681-685
- 4.10 Reproduit, avec la permission de Elsevier Science, J. Peto, J.T. Hodgson, F.E. Matthews, J.R. Jones (1995) Continuing increase in mesothelioma mortality in Britain. *Lancet*, 345(8949): 535-539
- 4.11 Anti-Cancer Council of Victoria, Australie/IARC Press
- 4.12 Graphics and Audiovisual section, NCI Office of Cancer Communications, USA
- 4.13 The Cancer Council New South Wales and the NSW Health Department, Australie
- 4.14 GLOBOCAN 2000*
- 4.15 & 4.16 OMS (2000) Technologie de la santé et produits pharmaceutiques, 1997 data <http://www.who.int/vaccines-surveillance/graphics/htmls/hepbprev.htm> and <http://www.who.int/vaccines-surveillance/graphics/htmls/hepb.htm>
- 4.17 J.Y. Scoazec, France
- 4.18 G. Kirk, USA/Adapté d'après P. Pisani, D.M. Parkin, N. Muñoz, J. Ferlay (1997) Cancer and infection: estimates of the attributable fraction in 1990. *Cancer Epidemiol Biomarkers Prev*, 6(6): 387-400
- 4.19 G.Kirk, USA.
- 4.20 IARC Press
- 4.21 W.J. Edmunds, G.F. Medley, D.J. Nokes, A.J. Hall and H.C. Whittle (1993) The influence of age on the development of the hepatitis B carrier state. *Proc R Soc Lond B*,

- 253, 197-201. Avec la permission de la Royal Society.
- 4.22 - 4.24 IARC*Press*
- 4.25 Graphics and Audiovisual section, NCI Office of Cancer Communications, USA
- 4.26 C.R. Boland, F.A. Sinicropo, D.E. Brenner, J.M. Carethers (2000) Colorectal cancer prevention and treatment. *Gastroenterology*, 118(2 Suppl 1): S115-28, avec la permission de la W.B. Saunders Company
- 4.27 IARC*Press*
- 4.28 B. Marincek, Institut für Diagnostische Radiologie, UniversitätsSpital, Ramistrasse 100, CH-8091 Zürich, Suisse
- 4.29 R. Sankaranarayanan, CIRC
- 4.30 Copyright GE Medical Systems
- 4.31 P. Pisani, CIRC
- 4.32 D.M. Parkin et al. (2001) *Eur J Cancer*, 37, suppl.8: S4-66
- 4.33 A. M. Thompson, Royaume-Uni
- 4.34 Wellcome Trust Medical Photographic Library, Royaume-Uni
- 4.35 Graphics and Audiovisual section, NCI Office of Cancer Communications, USA
- 4.36 Tiré de *Radiol Clin North Am*, 38, L. Tabar, B. Vitak, H.H. Chen, S.W. Duffy, M.F. Yen et al., The Swedish Two-County Trial twenty years later. Updated mortality results and new insights from long-term follow-up, 625-651, copyright (2000), avec la permission de Elsevier Science
- 4.37 Wellcome Trust Medical Photographic Library, Royaume-Uni
- 4.38 D.M. Parkin et al. (2001) *Eur J Cancer*, 37, suppl.8: S4-66
- 4.39 R. LiPuma, Prostate Cancer Education Council, 300 South Jackson Street, Suite 540 Denver, CO 80209, USA.
- 4.40 C.A. Rubio, Pathologie gastrointestinale et hépatique, Département de Pathologie, Institut Karolinska, 171 76 Stockholm, Suède
- 4.41 D.M. Parkin et al. (2001) *Eur J Cancer*, 37, suppl.8: S4-66
- 4.42 Prévention et Biologie, SA, 29-33 Rue de Metz, 94170 Le Perreux, France
- 4.43 D.M. Parkin et al. (2001) *Eur J Cancer*, 37, suppl.8: S4-66
- 4.44 IARC*Press*
- 4.45 D.M. Parkin et al. (2001) *Eur J Cancer*, 37, suppl.8: S4-66
- 4.46 Adapté de M.R. Law, J.K. Morris, N.J. Wald (1999) The importance of age in screening for cancer. *J Med Screen*, 6(1): 16-20, avec la permission du BMJ Publishing Group
- 4.47 R. Sankaranarayanan, CIRC
- 4.48 IARC*Press*
- 4.49 - 4.52 R. Sankaranarayanan, CIRC
- 4.53 A & B H. Ohgaki, CIRC
- 4.53 CR. Lambert, CIRC
- 4.54 D.M. Parkin et al. (2001) *Eur J Cancer*, 37, suppl.8: S4-66
- 4.55 Adapté du Tableau 2, Y. Tsubono and S. Hisamichi (2000) Screening for gastric cancer in Japan. *Gastric cancer*, 3: 9-18. Copyright Springer-Verlag
- 5.1 GLOBOCAN 2000*
- 5.2 Graphics and Audiovisual section, NCI Office of Cancer Communications, USA
- 5.3 B.W. Stewart, Australie
- 5.4 D.M. Parkin et al. (2001) *Eur J Cancer*, 37, suppl.8: S4-66
- 5.5 J.A. Baron and T.E. Rohan, Tobacco, in D. Schottenfeld and J.F. Fraumeni Jr. eds (1996) *Cancer Epidemiology and Prevention*, 2nd edition, Oxford University Press, Royaume-Uni
- 5.6 P. Boffetta, CIRC/Adapté de J.H. Lubin, W.J. Blot (1984) Assessment of lung cancer risk factors by histologic category. *J Natl Cancer Inst*, 73: 383-389
- 5.7 B. Marincek, Institut für Diagnostische Radiologie, UniversitätsSpital, Ramistrasse 100, CH-8091 Zürich, Suisse
- 5.8 F. Berger et J.Y. Scoazec, Laboratoire d'Anatomo-Pathologie, Hôpital Edouard Herriot, Place d'Arsonval, 69003 Lyon, France
- 5.9 P. Boffetta, CIRC
- 5.10 CIRC/SEER/Registre du Cancer d'Osaka†
- 5.11 IARC*Press*/Département de Pathologie, Université de Zurich, Suisse
- 5.12 GLOBOCAN 2000*
- 5.13 Wellcome Trust Medical Photographic Library, Royaume-Uni
- 5.14 Von Kantor & Associates Inc., Ft. Lauderdale FL, USA/www.lectureslides.com
- 5.15 A. M. Thompson, Royaume-Uni
- 5.16 & 5.17 F. Berger et J.Y. Scoazec, Laboratoire d'Anatomo-Pathologie, Hôpital Edouard Herriot, Place d'Arsonval, 69003 Lyon, France
- 5.18 P. Kleihues, CIRC
- 5.19 D.M. Parkin et al. (2001) *Eur J Cancer*, 37, suppl.8: S4-66
- 5.20 Von Kantor & Associates Inc., Ft. Lauderdale FL, USA/www.lectureslides.com
- 5.21 CIRC/SEER/Registre du Cancer d'Osaka†
- 5.22 IARC*Press*
- 5.23 GLOBOCAN 2000*
- 5.24 D.M. Parkin et al. (2001) *Eur J Cancer*, 37, suppl.8: S4-66
- 5.25 N. Matsukura, Japon
- 5.26 H. Ohgaki, CIRC
- 5.27 F. Berger et J.Y. Scoazec, Laboratoire d'Anatomo-Pathologie, Hôpital Edouard Herriot, Place d'Arsonval, 69003 Lyon, France
- 5.28 CIRC/SEER/Registre du Cancer d'Osaka†
- 5.29 GLOBOCAN 2000*
- 5.30 IARC*Press*
- 5.31 Reproduit d'après *Eur J Cancer*, Vol 35, No 3, Ilyas M, Straub J, Tomlinson IPM, Bodmer W, Genetic pathways in colorectal and other cancers, 335-351, copyright(1999), avec la permission de Elsevier Science
- 5.32 - 5.34 F. Berger et J.Y. Scoazec, Laboratoire d'Anatomo-Pathologie, Hôpital Edouard Herriot, Place d'Arsonval, 69003 Lyon, France
- 5.35 C. Fenoglio-Preiser, Department of Pathology, University of Cincinnati, School of Medicine, 231 Bethesda Avenue, POB 670529, Cincinnati, OH 45267-0529, USA
- 5.36 CIRC/SEER/Registre du Cancer d'Osaka†

- 5.37 & 5.38 GLOBOCAN 2000*
- 5.39 IARC*Press*
- 5.40 B. Marincek, Institut für Diagnostische Radiologie, UniversitätsSpital, Ramistrasse 100, CH-8091 Zürich, Suisse
- 5.41 - 5.43 F. Berger et J.Y. Scoazec, Laboratoire d'Anatomo-Pathologie, Hôpital Edouard Herriot, Place d'Arsonval, 69003 Lyon, France
- 5.44 CIRC/SEER/Registre du Cancer d'Osaka†
- 5.45 GLOBOCAN 2000*
- 5.46 D.M. Parkin et al. (2001) *Eur J Cancer*, 37, suppl.8: S4-66
- 5.47 L. Denis, Belgium, et K. Griffiths, Royaume-Uni
- 5.48 & 5.49 F. Berger et J.Y. Scoazec, Laboratoire d'Anatomo-Pathologie, Hôpital Edouard Herriot, Place d'Arsonval, 69003 Lyon, France
- 5.50 Adapté d'après la Figure 4C. Abate-Shen, M.M. Shen (2000) Molecular genetics of prostate cancer. *Genes Dev*, 14(19): 2410-2434
- 5.51 GLOBOCAN 2000*
- 5.52 P. Kleihues, CIRC
- 5.53 M.K. Rosenblum, Department of Pathology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York NY 10021, USA
- 5.54 F. Berger et J.Y. Scoazec, Laboratoire d'Anatomo-Pathologie, Hôpital Edouard Herriot, Place d'Arsonval, 69003 Lyon, France
- 5.55 Adapté d'après la Figure 6, R.S. Chaganti, J. Houldsworth (2000) Genetics and biology of adult human male germ cell tumors. *Cancer Res*, 60(6): 1475-1482
- 5.56 CIRC/SEER/Registre du Cancer d'Osaka†
- 5.57 GLOBOCAN 2000*
- 5.58 WHO/TDR Image Library/ Crump
- 5.59 & 5.60 R. Sankaranarayanan, CIRC
- 5.61 F. Berger et J.Y. Scoazec, Laboratoire d'Anatomo-Pathologie, Hôpital Edouard Herriot, Place d'Arsonval, 69003 Lyon, France
- 5.62 CIRC/SEER/Registre du Cancer d'Osaka†
- 5.63 GLOBOCAN 2000*
- 5.64 F. Berger et J.Y. Scoazec, Laboratoire d'Anatomo-Pathologie, Hôpital Edouard Herriot, Place d'Arsonval, 69003 Lyon, France
- 5.65 CIRC/SEER/Registre du Cancer d'Osaka
- 5.66 M. Esteller, J. Xercavins, J. Reventos (1999) Advances in the molecular genetics of endometrial cancer. *Oncology Reports* 6 (6): 1377-1382
- 5.67 GLOBOCAN 2000*
- 5.68 B. Marincek, Institut für Diagnostische Radiologie, UniversitätsSpital, Ramistrasse 100, CH-8091 Zürich, Suisse
- 5.69 Wellcome Trust Medical Photographic Library, Royaume-Uni
- 5.70 F. Berger et J.Y. Scoazec, Laboratoire d'Anatomo-Pathologie, Hôpital Edouard Herriot, Place d'Arsonval, 69003 LyonFrance
- 5.71 CIRC/SEER/Registre du Cancer d'Osaka†
- 5.72 GLOBOCAN 2000*
- 5.73 & 5.74 IARC*Press*
- 5.75 D.M. Parkin et al. (2001) *Eur J Cancer*, 37, suppl.8: S4-665.76A.M. Thompson, Royaume-Uni
- 5.77 F. Berger et J.Y. Scoazec, Laboratoire d'Anatomo-Pathologie, Hôpital Edouard Herriot, Place d'Arsonval, 69003 Lyon, France
- 5.78 C. Fenoglio-Preiser, Department of Pathology, University of Cincinnati, School of Medicine, 231 Bethesda Avenue, POB 670529, Cincinnati, OH 45267-0529, USA
- 5.79 M. Werner, Institut de Pathologie, Technische Universität München, Ismaninger Strasse 22, D-81675 Munich, Allemagne
- 5.80 CIRC/SEER/Registre du Cancer d'Osaka†
- 5.81 GLOBOCAN 2000*
- 5.82 P. Brennan, CIRC/ Adapté d'après P. Brennan, O. Bogillot, S. Cordier et al. (2000) Cigarette smoking and bladder cancer in men: a pooled analysis of 11 case-control studies. *Int J Cancer*, 86(2): 289-294
- 5.83 WHO/ TDR Image Library/ Manderson
- 5.84 & 5.85 F. Berger et J.Y. Scoazec, Laboratoire d'Anatomo-Pathologie, Hôpital Edouard Herriot, Place d'Arsonval, 69003 Lyon, France
- 5.86 Reproduit d'après *Urologic Clinics of North America*, 27(1), R. Lee and M.J. Droller, The natural history of bladder cancer, 1-13, copyright (2000), avec la permission de Elsevier Science
- 5.87 CIRC/SEER/Registre du Cancer d'Osaka†
- 5.88 - 5.90 GLOBOCAN 2000*
- 5.91 - 5.93 R. Sankaranarayanan, CIRC
- 5.94 F. Berger et J.Y. Scoazec, Laboratoire d'Anatomo-Pathologie, Hôpital Edouard Herriot, Place d'Arsonval, 69003 Lyon, France
- 5.95 CIRC/SEER/Registre du Cancer d'Osaka†
- 5.96 D. Sidransky (1997) Tumor suppressor genes, in V.T. DeVita Jr., et al., eds, *Cancer: Principles and Practice of Oncology*, 5th edition, Lippincott-Raven, p 737
- 5.97 GLOBOCAN 2000*
- 5.98 Wellcome Trust Medical Photographic Library, Royaume-Uni
- 5.99 L.A.G. Ries, M.P. Eisner, C.L. Kosary, B.F. Hankey, B.A. Miller, L. Clegg, B.K. Edwards eds (2001) *SEER Cancer Statistics Review, 1973-1998*, National Cancer Institute, Bethesda, MD
- 5.100 GLOBOCAN 2000*
- 5.101 E.S. Jaffe, Laboratory of Pathology, NIH, Building 10, Room 2N-202, 10 Center Drive MSC-1500, Bethesda, MD 20892-1500, USA
- 5.102 F. Berger et J.Y. Scoazec, Laboratoire d'Anatomo-Pathologie, Hôpital Edouard Herriot, Place d'Arsonval, 69003 Lyon, France
- 5.103 H. Stein, Institut für Pathologie, Freie Universität Berlin, Universitätsklinikum Steglitz, Hindenburgdamm 30,D 12200 Berlin, Allemagne
- 5.104 E.S. Jaffe, Laboratory of Pathology, NIH, building 10, Room 2N-202, 10 Center Drive MSC-1500, Bethesda, MD 20892-1500, USA
- 5.105 Reproduit avec la permission de A.A. Alizadeh, M.B.

- Eisen, R.E. Davis, C. Ma, I.S. Lossos et al. (2000) Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. *Nature*, 403(6769): 503-511. Copyright 2000, Macmillan Magazines Ltd.
- 5.106 & 5.107 CIRC/SEER/Registre du Cancer d'Osaka†
- 5.108 GLOBOCAN 2000*
- 5.109 Los Alamos National Laboratory/SPL/Cosmos
- 5.110 L.A.G. Ries, M.P. Eisner, C.L. Kosary, B.F. Hankey, B.A. Miller et al., eds (2001) *SEER Cancer Statistics Review, 1973-1998*, National Cancer Institute, Bethesda MD, USA
- 5.111 A & B R.D. Brunning, Department of Laboratory Medicine and Pathology, University of Minnesota Hospital, 420 Delaware Street S.E., Box 609, Minneapolis, MN 55455-0385, USA
- 5.112 Adapté d'après une figure de J. Melo, Department of Haematology, ISCM, Hammersmith Hospital, Ducane Road, London W12 0NN, Royaume-Uni
- 5.113 A & B G. Flandrin, Laboratoire Central d'Hématologie, Hôpital Necker, 149 rue de Sèvres, F-75015 Paris, France
- 5.114 R.D. Brunning, Department of Laboratory Medicine and Pathology, University of Minnesota Hospital, 420 Delaware Street S.E., Box 609, Minneapolis, MN 55455-0385, USA
- 5.115 Avec la permission de J.A. Squire, de V.D. Markovic, D. Bouman, J. Bayani, J. Al-Maghrabi, S. Kamel-Reid et al. (2000) Lack of BCR/ABL reciprocal fusion in variant Philadelphia chromosome translocations: a use of double fusion signal FISH and spectral karyotyping. *Leukemia*, 14(6):1157-1160
- 5.116 B. Hirsch, Department of Laboratory Medicine and Pathology, University of Minnesota School of Medicine, 420 Delaware St. SE, Minneapolis, MN 55455, USA
- 5.117 J.W. Vardiman, Department of Pathology, University of Chicago Medical Center, 5841 South Maryland Ave., MC0008 Romm TW-055, Chicago, IL 60637-1470, USA
- 5.118 CIRC/SEER/Registre du Cancer d'Osaka†
- 5.119 & 5.120 GLOBOCAN 2000*
- 5.121 Graphics and Audiovisual section, NCI Office of Cancer Communications, USA
- 5.122 G. Zamboni, Dépt de Pathologie, Université de Vérone, Strada Le Grazie, I-37134 Vérone, Italie
- 5.123 G. Klöppel, Institut de Pathologie, Université de Kiel, Michaelistrasse 11, D-24105 Kiel, Allemagne
- 5.124 P. Vogt, Département de Pathologie, Hôpital universitaire USZ, Schmelzbergstrasse 12, CH-8091 Zurich, Suisse
- 5.125 F. Berger et J.Y. Scoazec, Laboratoire d'Anatomo-Pathologie, Hôpital Edouard Herriot, Place d'Arsonval, 69003 Lyon, France
- 5.126 CIRC/SEER/Registre du Cancer d'Osaka†
- 5.127 GLOBOCAN 2000*
- 5.128 Données du New South Wales Central Cancer Registry†, Australie
- 5.129 B.W. Stewart, Australie
- 5.130 - 5.134 W. McCarthy, Australie
- 5.135 GLOBOCAN 2000*
- 5.136 Agence internationale de l'Energie atomique, Vienne
- 5.137 GLOBOCAN 2000*
- 5.138 Agence internationale de l'Energie atomique, Vienne
- 5.139 F. Berger et J.Y. Scoazec, Laboratoire d'Anatomo-Pathologie, Hôpital Edouard Herriot, Place d'Arsonval, 69003, Lyon, France
- 5.140 Adapté d'après la Figure 2, D.L. Learoyd, M. Messina, J. Zedenius, B.G. Robinson (2000) Molecular genetics of thyroid tumours and surgical decision making. *World J Surg*, 24, 923-933
- 5.141 CIRC/SEER/Registre du Cancer d'Osaka†
- 5.142 & 5.143 GLOBOCAN 2000*
- 5.144 Wellcome Trust Medical Photographic Library, Royaume-Uni
- 5.145 B. Marincek, Institut für Diagnostische Radiologie, UniversitätsSpital, Ramistrasse 100, CH-8091 Zurich, Suisse
- 5.146 Public Health Image Library, CDC, USA/Dr Edwin P. Ewing, Jr.
- 5.147 F. Berger et J.Y. Scoazec, Laboratoire d'Anatomo-Pathologie, Hôpital Edouard Herriot, Place d'Arsonval, 69003 Lyon, France
- 5.148 CIRC/SEER/Registre du Cancer d'Osaka†
- 5.149 J. Ferlay, F.I. Bray, R. Sankila, D.M. Parkin eds (1999) *EUCAN90: Cancer Incidence Mortality and Prevalence in the European Union* (IARC CancerBase No. 4), Lyon, IARC Press
- 5.150 P. Kleihues, CIRC
- 5.151 P.C. Burger, Pathology Building, Room 706, The Johns Hopkins Hospital, 600 Wolfe Street, Baltimore, MD 21287, USA
- 5.152 H. Ohgaki, CIRC
- 5.153 P. Kleihues, CIRC
- 5.154 A. Vital, Laboratoire de Neuropathologie, Université Victor Segalen, Bordeaux 2, 146, rue Léo-Saignat, 33000 Bordeaux, France
- 6.1 Wellcome Trust Medical Photographic Library, Royaume-Uni
- 6.2 - 6.5 G. Maddern, Australie
- 6.6 Varian Medical Systems, Palo Alto, USA
- 6.7-6.8 Varian Medical Systems Royaume-Uni Ltd.
- 6.9 & 6.10 Graphics and Audiovisual section, NCI Office of Cancer Communications, USA
- 6.11 K. Sikora, Royaume-Uni
- 6.12 Modifié, d'après C.M. Haskell, ed (1995) *Cancer Treatment, 4th Edition*, W.B. Saunders/Reproduit d'après W.E. Ross et al., Pharmacology and Therapeutics, copyright 1987, Vol. 32, p. 89, avec la permission de Elsevier Science
- 6.13 H. Stein, Institut für Pathologie, Freie Universität Berlin, Universitätsklinikum Steglitz, Hindenburgdamm 30, D-12200 Berlin, Allemagne
- 6.14 K. Sikora, Royaume-Uni
- 6.15 A. Villunger and A. Strasser (1999) The great escape: is immune evasion required for tumor progression? *Nat Med*, 5(8): 874-5
- 6.16 P. Hersey, Australie

- 6.17 K.R. Dumon, H. Ishii, L.Y. Fong, N. Zanesi, V. Fidanza et al., (2001) FHIT gene therapy prevents tumor development in Fhit-deficient mice. *Proc Natl Acad Sci USA*, 98: 3346-3351. Copyright (2001) National Academy of Sciences, USA
- 6.18 Von Kantor and Associates Inc., Fort. Lauderdale FL, USA/www.lectureslides.com
- 6.19 A. M. Thompson, Royaume-Uni
- 6.20 Permission du Palliative Care Council of South Australia
- 6.21 Adapté d'après OMS(1996) *Traitement de la douleur cancéreuse*, 2ème édition, Genève, Organisation mondiale de la Santé /données pour 1999 de David E. Joranson, Pain & Policy Studies Group, WHO Collaborating Center for Policy and Communications and the International Narcotics Control Board, United Nations Demographic Yearbook, 1999.
- 6.22 Données de David E. Joranson, Pain & Policy Studies Group, WHO collaborating Center for Policy and Communications
- 6.23 B. Cassileth, USA
7. 1 & 7.2 IARCPress
- 7.3 C. Sepulveda, OMS
- 7.4 Union internationale contre le Cancer (UICC), 3, rue du Conseil-Général, CH-1205 Genève, Suisse
- 7.5 Initiative pour un monde sans tabac, Organisation mondiale de la Santé, Avenue Appia 20 1211, Genève 27 Suisse
- 7.6 M. Imperi (2000) *BMJ*, 321, photo de couverture, avec la permission du *BMJ* Publishing Group.
- 7.7 E. Lucas, CIRC
- 7.8 WHO/TDR Image Library/Haaland
- 7.9 R. Sankaranarayanan, CIRC
- 7.10 G. Mollon, CIRC
- 7.11 - 7.13 E. Lucas, CIRC
- 7.14 OMS (1998) *Rapport sur la santé dans le monde 1998. La vie au 21ème siècle : Une perspective pour tous*, Genève, Organisation mondiale de la Santé, p43
- 7.15 & 7.16 WHO/HPR/TDR Image Library/Crump
- 7.17 OMS (1998) *Rapport sur la santé dans le monde 1998. La vie au 21ème siècle : Une perspective pour tous*. Genève, Organisation mondiale de la Santé, p48
- 7.18 Trust Medical Photographic Library, Royaume-Uni
- 2.5 & 2.6 P. Boffetta, CIRC
- 2.7 - 2.10 J. Rice, CIRC/*Programme des Monographies du CIRC*
- 2.11 P. Boffetta, CIRC
- 2.12 P. Boffetta, CIRC/Centre OMS Européen pour l'Environnement et la Santé, 1995
- 2.13 - 2.15 J. Rice, CIRC/*Programme des Monographies du CIRC*
- 2.16 IARCPress/UNSCEAR, 1994
- 2.17 E. Cardis, CIRC
- 2.18 S. Franceschi, CIRC
- 2.19 J. Rice, CIRC/*Programme des Monographies du CIRC*
- 2.20 & 2.21 D. Goldgar, CIRC
- 2.22 S. Franceschi, F. Parazzini, E. Negri, M. Booth, C. La Vecchia, V. Beral, A. Tzonou and D. Trichopoulos (1991) Pooled analysis of 3 European case-control studies of epithelial ovarian cancer III. Oral contraceptive use. *Int J. Cancer*, 49: 61-65
- 3.1 Adapté de H. Marquardt, Chemical carcinogenesis, in H. Marquardt, S.G. Schafer, R. McClellan and F. Welsch,eds (1999). *Toxicology*, Academic Press, San Diego,151-178
- 3.2 & 3.3 P. Hainaut, CIRC
- 3.4 H. Yamasaki, Y. Omori, M.L. Zaidan-Dagli, N. Mironov, M. Mesnil et al. (1999) Genetic and epigenetic changes of intercellular communication genes during multistage carcinogenesis, *Cancer Detect and Prev*, 23: 273-279
- 3.5 & 3.6 S. Eccles, Royaume-Uni
- 3.7 Reproduit avec la permission de Nature, L.A. Liotta, E.C. Kohn (2001) The microenvironment of the tumour-host interface, *Nature*, 411: 375-379, copyright 2001, Macmillan Magazines Ltd.
- 3.8 A. Sasco, CIRC
- 4.1 & 4.2 C.J.L. Murray, A.D. Lopez, Assessing the burden of disease that can be attributed to specific risk factors. In *Ad Hoc Committee on Health Research Relating to Future Intervention Options. Investing in Health Research and Development*. Organisation mondiale de la Santé, Genève, 1996
- 4.3 A. Sasco, CIRC
- 4.4 CIRC (1999) *Re-evaluation of some Organic Chemicals, Hydrazine and Hydrogen Peroxide (IARC Monographs Vol. 71)*, Lyon, IARCPress
- 4.5 USA EPA (2000) *Latest Findings on National Air Quality: 1999 Status and Trends*, US Environmental Protection Agency
- 4.6 OMS (1999) *Directives de l'OMS sur la qualité de l'air*, Genève, OMS
- 4.7 S. Yamamura (2001) Drinking water guidelines and standards, in United Nations synthesis report on arsenic in drinking water, United Nations (projet), http://www.who.int/entity/water_sanitation_health/dwq/en/arsenicun5.pdf
- 4.8 B.W. Stewart, Australie
- 4.9 Adapté d'après le Tableau 1, Prophylactic vaccines under development, in A. Kols and J. Sherris (2000) *HPV Vaccines: Promise and Challenges. Alliance pour la prévention du cancer du col utérin*, PATH
- 4.10 & 4.11 S. Franceschi et N. Muñoz, CIRC
- 4.12 H. Vainio, CIRC
- 4.13 & 4.14 L. Denis, Belgique

Tableaux

- 2.1 & 2.2 Reproduit de *Eur J Cancer Prev*, Vol. 8, M. Pandey, A. Mathew, M.K. Nair. Global perspective of tobacco habits and lung cancer: a lesson for third world countries, 271-9, Copyright 1999, avec la permission de Elsevier Science
- 2.3 Adapté de N.J. Wald and A.K. Hackshaw (1996) *Br Med Bulletin*, 52 (1): 3-11 (et de the American Cancer Study (CPSII)), avec la permission de Oxford University Press
- 2.4 H. Boeing, Alcohol and risk of cancer of the upper gastrointestinal tract: first analysis of the EPIC data. In: E. Riboli and R. Lambert eds (2002) *Nutrition and Lifestyle: Opportunities for Cancer Prevention (IARC Scientific Publications No. 156)*. Lyon, IARCPress

- 4.15 & 4.16 R. Lambert, CIRC
- 4.17 R. Lambert, CIRC/Adapté, d'après J.S. Mandel, J.H. Bond, T.R. Church, D.C. Snover, G.M. Bradley et al. (1993) Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. *N Engl J Med*, 328:1365-1371
- 4.18 IARC Working Group on Cervical Cancer Screening (1986) Summary chapter, Screening for Cancer of the Uterine Cervix. (*IARC Scientific Publications No. 76*), Lyon, IARC Press
- 4.19 R. Sankaranarayanan, CIRC
- 5.1 P. Boffetta, CIRC
- 5.2 A. Sasco, CIRC /Données du Tableau 36.2-23, Cancer of the Breast, in V.T. DeVita Jr. et al., eds (1997) *Cancer: Principles and Practice of Oncology, 5th Edition*, Lippincott-Raven
- 5.2 B Munoz et al. *N Engl J Med* 348:518-527 (2003)
- 5.3 H. Ohgaki, CIRC
- 5.4 L. Raymond, J. Young M. Parkin S. Whelan and J. Ferlay , (1997) *Cancer Incidence in Five Continents*, Vol. VII, IARC Press
- 5.5 L.A.G. Ries, M.P. Eisner, C.L. Kosary, B.F. Hankey, B.A. Miller et al., eds (2001) *SEER Cancer Statistics Review, 1973-1998*, National Cancer Institute, Bethesda MD, USA
- 5.6 & 5.7 P. Hainaut, CIRC
- 5.8 L. Denis, Belgique
- 5.9 T. Shimoda, Department of Clinical Laboratory, National Cancer Center Hospital, 5-1-1 Tsukiji Chuo Ku, 104-0045 Tokyo, Japon
- 5.10 Adapté d'après Anon. (1997) A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. *Blood*, 89: 3909-3918
- 5.11 G. Young, Australie
- 5.12 & 5.13 G. Klöppel, Institut de Pathologie, Université de Kiel, Michaelistrasse 11, D-24105 Kiel, Allemagne
- 5.14 W. McCarthy, Australie
- 5.15 Données de E. van den Berg, T. Dijkhuizen (1999) Classification of renal cell cancer based on (cyto)genetic analysis. *Contrib Nephrol*, 128: 51-61; A. Bernheim, A. Vagner-Capodano, J. Couturier, et le Groupe français de cytogénétique oncologique (2000) De la cytogénétique à la cytogénomie oncologique. *Médecine/ Sciences*, 16: 528-539
- 5.16 & 5.17 P. Kleihues, CIRC
- 6.1 Table 15-12, p301, S. Rosenberg, Principles of cancer management: surgical oncology, in V.T. DeVita Jr., S. Hellman, S.A. Rosenberg, eds (1997) *Cancer: Principles and Practice of Oncology, 5th edition*, copyright Lippincott, Williams & Wilkins
- 6.2 G.H. Sakorafas (2001) Breast cancer surgery—historical evolution, current status and future perspectives. *Acta Oncol*, 40(1): 5-18
- 6.3 A.J.A. Bremers, E.J.Th. Rutgers, C.J.H. van de Velde (1999) Cancer surgery: the last 25 years. *Cancer Treat Rev*, 25:333-353
- 6.4 - 6.8 K. Sikora, Royaume-Uni
- 6.9 P. Hersey, Australie
- 6.10 Adapté de S.J. Clarke, Drug resistance, in J.F. Bishop, ed (1999) *Cancer Facts. A Concise Oncology Text*, Australia, Harwood Academic Publishers, 67-71
- 6.11 K. Shin, USA
- 6.12 J.A. DeLisa, *Cancer*, Vol. 92, No. 4 Suppl., 2001, pp. 970-974. Copyright (2001) American Cancer Society. Reproduit avec la permission de Wiley-Liss, Inc., une filiale de John Wiley & Sons, Inc.
- 6.13 & 6.14 K. Shin, USA
- 7.1 & 7.2 R. Sankaranarayanan, CIRC

Note:

* GLOBOCAN 2000 J. Ferlay, F.I. Bray, D.M. Parkin, P. Pisani (2001) *Globocan 2000: Cancer Incidence and Mortality Worldwide (IARC CancerBase No. 5)*, Lyon, IARC Press.
 † IARC/SEER/Registre du Cancer d'Osaka.

R. Sankaranarayanan, R.J. Black and D.M. Parkin (1998) *Cancer survival in developing countries (IARC Scientific Publications No. 145)*, Lyon, IARC Press;

F. Berrino, R. Capocaccia, J. Esteve, F. Berrino, J. Capocaccia et al. (1999) *Survival of cancer patients in Europe: the EURO CARE-2 study (IARC Publications No. 151)*, Lyon, IARC Press;

L.A.G. Ries, M.P. Eisner, C.L. Kosary, B.F. Hankey, B.A. Miller et al., eds (2001) *SEER Cancer Statistics Review, 1973-1998*, National Cancer Institute. Bethesda, MD; http://seer.cancer.gov/csr/1973_1999/

Registre du cancer d'Osaka, Japon: données pour 1992 utilisées. http://www.mc.pref.osaka.jp/ocr_e/ocr/